Scientific, Rigorous, Precise. High-Purity Reagents for Epigenetic and Neurodevelopmental Drug Discovery.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CHD2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CHD2 Recombinant Protein (Chromodomains/ATPase Domain) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Sf9/HEK293 expressed. |
View CHD2 Products |
| Gene Delivery | CHD2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and rescue assays. |
View CHD2 Products |
| Benchmark Ab | Anti-CHD2 Control Antibody Recombinant positive control for Western Blot, ChIP, and IHC. |
View CHD2 Products |
| Validator | CHD2 siRNA Set For knockdown verification in functional and phenotypic assays. |
View CHD2 Products |
| Related Target A | CHD1 Paralogous chromatin remodeling enzyme; critical for selectivity and off-target screening. |
View CHD1 Products |
| Related Target B | CHD4 Core component of the NuRD complex; key comparator in disease-associated chromatin remodeling. |
View CHD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High Molecular Weight Expression (>200 kDa) | Domain-specific truncations (Chromodomains 1-2, Helicase domain) optimized for high solubility and >95% purity. |
| Selectivity Over Paralogs (CHD1, CHD3, CHD4) | Homologue panel proteins strictly verified by mass spectrometry and sequence alignment. |
| Lack of Controls | ChIP-validated benchmark antibodies included for chromatin binding assays. |
| False Positives | Validated siRNA pool included for target specificity and functional knockdown checks. |
Live CHD2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CHD2 therapeutics is intensifying, with major players shifting focus from traditional gene replacement to targeted small molecule modulators, PROTACs, and genetic therapies (ASOs/mRNA). As first-generation therapies for developmental and epileptic encephalopathy 9 (EE9) and CHD2-related neurodevelopmental disorders reach preclinical maturation, the next wave of R&D is targeting epigenetic modulation in hematological malignancies and solid tumors where CHD2 dysregulation drives oncogenesis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy / ASO | Academic Medical Centers, Biotech Startups | Epileptic Encephalopathy 9 (EE9), Autism Spectrum Disorder | Functional rescue assays (Need high-titer Lentivirus for stable expression) |
| Small Molecule Inhibitors | Epigenetics-focused Biopharma | Chronic Lymphocytic Leukemia (CLL), Lymphomas | Enzymatic ATPase activity assays (Need high-purity recombinant ATPase domain) |
| PROTACs / Degraders | Targeted Protein Degradation (TPD) Pioneers | Refractory Solid Tumors, Hematological Cancers | Binary/Ternary complex binding validation (Need sequence-verified Chromodomain proteins) |